We analyzed one assertion on whether apitegromab combined with tirzepatide shifts weight loss from muscle to fat, and found no studies that contradict it. The evidence we’ve reviewed suggests that when these two drugs are taken together, a smaller share of the weight lost comes from muscle, and a larger share comes from fat, compared to tirzepatide alone — without changing the total amount of fat lost [1]. This means the body may be preserving more muscle while still losing the same amount of fat as it would with tirzepatide by itself. We don’t know why this might happen, because the evidence doesn’t explain the biological mechanism. We also don’t know how long this effect lasts, or whether it applies to everyone. The single assertion we reviewed is based on data from one source, and we haven’t seen results from multiple trials or different populations. So far, the pattern points toward a possible benefit in how weight loss is distributed — less muscle loss, same fat loss — but we can’t say this is true for all people or in all settings. More studies would help us understand if this holds across different ages, activity levels, or health conditions. If you’re considering this combination, it may mean you could lose fat without losing as much muscle, which could matter for strength and metabolism. But we don’t yet know how this affects long-term health or whether it’s safe or effective for you personally.